Save this information in writing
Drugs that block the action of DPP-4 are called DPP-4 inhibitors and these have been used in the treatment of type 2 diabetes for many years
The side effect profile mirrors what you'd expect from GLP-1-based drugs: Nausea, particularly when starting or increasing the dose Diarrhoea and, less often, constipation Reduced appetite (which is, of course, partly the point) Tiredness in the first few weeks Occasional vomiting at higher doses In the Phase 2 trials, most side effects were rated mild to moderate and tended to settle as the body adjusted
In the 4-week study, PG-102 was administered at 2, 6, or 20 mg/kg ( n = 5/sex for vehicle and 20 mg/kg
Melanotan-2 remains the only available pharmacological tool allowing the simultaneous study of the relative contributions of the four MCR receptors using selective antagonism protocols (HS024 for MC4R, JNJ-10229570 for MC3R, etc.)